Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.
You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!
If you have any problems with the registration process or your account login, please contact contact us.
ONGLYZA? (saxagliptin) Launched In The UK For The Treatment Of Type 2 Diabetes
Bristol-Myers Squibb Company and AstraZeneca announced the launch of ONGLYZA? (saxagliptin) in the UK for the treatment of Type 2 diabetes in adults, as add-on therapy with metformin, a thiazolidinedione or a sulphonylurea.